| Literature DB >> 31470870 |
Mohammad Reza Abbaszadegan1, Vahideh Keyvani2, Meysam Moghbeli3.
Abstract
BACKGROUND: Esophageal cancer is one of the leading causes of cancer related deaths among the Iranians. There is still a high ratio of mortality and low 5 years survival which are related to the late onset and diagnosis. Majority of patients refer for the treatment in advanced stages of tumor progression. MAIN BODY: It is required to define an efficient local panel of diagnostic and prognostic markers for the Iranians. Indeed such efficient specific panel of markers will pave the way to decrease the mortality rate and increase the 5 years survival among the Iranian patients via the early diagnosis and targeted therapy.Entities:
Keywords: Diagnosis; Esophageal cancer; Iran; Panel marker; Prognosis
Mesh:
Substances:
Year: 2019 PMID: 31470870 PMCID: PMC6717340 DOI: 10.1186/s13000-019-0875-4
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
All of the involved markers in esophageal cancer susceptibility among the Iranian patients
| Study (et al) | Year | Gene | Purpose | Population | Results |
|---|---|---|---|---|---|
| salehi [ | 2006 | eIF4E | Prognosis | 99 N/Ta | Over expression |
| MOGHBELI [ | 2014 | MSI1 | Diagnosis | 53 N/T | Correlation with sex |
| KAHKHAIE [ | 2014 | MUC1 | Prognosis | 50 N/T | Correlation with stage, grade, and lymph node |
| SEDIGHI [ | 2016 | MMP13 | Diagnosis and Prognosis | 66 patients 54 controls | Correlation with lymph node, tumor size, and survival |
| golyan [ | 2019 | MMP21 | Diagnosis and Prognosis | 58 N/T | Correlation with stage |
| SALEHI [ | 2016 | BRUCE | Diagnosis | 50 N/T | Correlation with stage |
| ABBASZADEGAN [ | 2008 | P16 | Diagnosis | 52 patients 50 controls | Hypermethylation |
| taghavi [ | 2010 | P16 | Diagnosis | 50 N/T | Hypermethylation |
| ABBASZADEGAN [ | 2005 | P16 | Diagnosis | 30 patients 30 controls | Hypermethylation |
| abedi-ardekani [ | 2011 | P53 | Diagnosis | 119 patients | Mutation |
| khalilipour [ | 2018 | KCNJ12 | Diagnosis | 9 patients | Mutation |
| forghanifard [ | 2019 | DIDO1 | Diagnosis | 50 N/T | Correlation with depth of invasion |
| Ghobadi [ | 2018 | CDKN2A | Prognosis | 123 patients | Polymorphism was correlated with ESCC risk |
| hashemi-bidokhti [ | 2017 | MAML1 | Diagnosis and Prognosis | 56 N/T | Over expression was correlated with depth of invasion, grade, stage, and sex |
| forghanifard [ | 2012 | MAML1, TWIST1 | Diagnosis and Prognosis | 55 N/T | Over expressions were correlated with lymph node metastasis and stage |
| MOGHBELI [ | 2013 | EGFR, PYGO2 | Diagnosis and Prognosis | 55 N/T | Correlation with stage and grade |
| FORGHANIFARD [ | 2014 | SALL4, SOX2 | Diagnosis | 50 N/T | Correlation with lymph node and depth of invasion |
| MAHMOUDIAN [ | 2017 | Cripto-1 | Diagnosis | 50 N/T | Correlation with tumor grade, stage, and location |
| MALLAK [ | 2016 | EVX1 | Diagnosis | 50 N/T | Correlation with lymph node and depth of invasion |
| forghanifard [ | 2018 | SIZN1 | Diagnosis | 50 N/T | Correlation with depth of invasion and lymph node metastasis |
| ANSARI [ | 2016 | miR-93 | Diagnosis | 30 N/T | Over expression |
| ANSARI [ | 2016 | miR-143 | Diagnosis | 30 N/T | Under expression |
| GHASEMI [ | 2018 | miR-371–373 | Diagnosis | 36 N/T | Over expression |
| sahebi [ | 2016 | Linc-ROR | Diagnosis | 30 N/T | Correlation with grade |
| maghsudlu [ | 2019 | miR-27a | Diagnosis and Prognosis | 30 N/T | Over expression |
| AKBARI [ | 2008 | BRCA2 | Diagnosis | 197 patients 254 controls | Mutation |
| forghanifard [ | 2011 | MAGE-A4 | Diagnosis and Prognosis | 41 N/T | Over expression |
aTumor tissues and normal margins